巨头赛诺菲:Dupilumab业绩高涨94%;过专利药物迎来黄昏
2023-08-05 22:00
举报
Dupixent(IL-4R a)业绩为16.34亿欧元,同比大增93.8%;Praluent(PCSK9)业绩仅为1.46亿欧元,同比增长18%;波立维Plavix业绩为5....
相关阅读
2023-02-27
2022-02-18
2023-11-07
2023-06-18
2021-11-18
2021-12-02
2021-11-20
2021-11-12
2023-03-16
2023-03-04
2023-01-31
